Pharmaceuticals

Biologics Manufacturing Market Forecast 2026–2035: Data Trends and Industry Insights

February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics manufacturing market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Biologics Manufacturing Market expected to grow between 2026 and 2030?

The biologics manufacturing market has experienced substantial growth in its size over recent years. It is projected to increase from $42.04 billion in 2025 to $50.69 billion in 2026, reflecting a compound annual growth rate (CAGR) of 20.6%. Historically, this expansion can be ascribed to elements such as the broader use of recombinant protein therapeutics, the initial integration of mammalian cell culture systems, an increase in vaccine manufacturing capacity, rising outsourcing of biologics production, and developments in purification technologies.

The biologics manufacturing market size is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $106.08 billion by 2030, expanding at a compound annual growth rate (CAGR) of 20.3%. This expansion during the forecast period is driven by factors such as the increasing demand for personalized biologics, rising investments in flexible manufacturing platforms, the broadening of biosimilar development, the growing adoption of digital bioprocessing tools, and a concentrated focus on cost-efficient large-scale production. Concurrently, major trends expected in the forecast period encompass the increasing adoption of single-use bioprocessing systems, the rising deployment of continuous biomanufacturing, a growing demand for high-volume monoclonal antibody production, the expansion of modular biologics facilities, and enhanced integration of advanced process control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30212&type=smp

Which Drivers Are Influencing Market Acceleration In The Biologics Manufacturing Market?

The expanding occurrence of chronic illnesses is anticipated to drive forward the growth of the biologics manufacturing market. Chronic diseases are enduring health conditions that manifest slowly and persist for extended durations, frequently demanding continuous medical care. The rising prevalence of these conditions is partly attributable to inactive lifestyles, given that prolonged sitting and minimal physical activity increase the risk of developing ailments such as heart conditions and diabetes. Biologics manufacturing plays a crucial role in enhancing chronic disease management by developing targeted therapies, proving effective for conditions including diabetes, cancer, and autoimmune disorders. It also lessens the disease burden through the provision of consistent, high-quality biologic medicines, which ultimately improves patient outcomes and the efficiency of treatment. For example, in June 2024, data from the National Health Service, a UK-based government department, indicated that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels, though not sufficiently high to be classified as diabetes) in 2023. This figure marked an 18% increase from 3,065,825 cases recorded in 2022. Therefore, the increasing prevalence of chronic diseases is a significant factor fueling the growth of the biologics manufacturing market.

What Segments Are Identified Within The Structure Of The Biologics Manufacturing Market?

The biologics manufacturing market covered in this report is segmented –

1) By Mode of Manufacturing: Contract Manufacturing, In-House Manufacturing

2) By Modality: Monoclonal Antibodies (mAbs), Biosimilar And Recombinant Proteins, Vaccines (recombinant/mRNA/Viral), Cell And Gene Therapies, Ribonucleic Acid-Based Therapeutics

3) By Disease Indication: Oncology, Autoimmune Disorders, Infectious Diseases, Neurological Disorders, Other Disease Indications

Subsegments:

1) By Contract Manufacturing: Mammalian Cell-Based Production, Microbial Fermentation Production, Cell-Free Protein Synthesis, Hybrid Manufacturing Systems

2) By In-House Manufacturing: Mammalian Cell Culture Production, Microbial Expression Systems, Continuous Bioprocessing, Single-Use Technology Production

What Industry Trends Are Transforming The Biologics Manufacturing Market?

Prominent companies in the biologics manufacturing market are concentrating on innovating advanced solutions, including integrated biologics contract development and manufacturing organization platforms, to optimize end-to-end biologics development, operational efficiency in production, and supply chain connectivity across diverse therapeutic approaches. An integrated biologics contract development and manufacturing organization (CDMO) platform represents a comprehensive framework that consolidates biologics development, production, and supply services within one cohesive system. For instance, in June 2023, Catalent Inc., a US-based contract development and manufacturing company, expanded its OneBio Suite for unified development, manufacturing, and supply across various biologic modalities. This enhanced OneBio Suite offers a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) platform that supports products like antibodies, cell and gene therapies, and mRNA-based therapeutics. It delivers complete services from early development to fill-finish and packaging through a single contract and standardized project management, facilitating faster development timelines, improved scalability, and seamless global supply integration.

Which Leading Companies Dominate The Biologics Manufacturing Market Share?

Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-biologics-manufacturing-market-report

How Does The Biologics Manufacturing Market Perform Across Major Global Regions?

North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biologics Manufacturing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30212&type=smp

Browse Through More Reports Similar to the Global Biologics Manufacturing Market 2026, By The Business Research Company

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Biologics Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795